Moleculin Biotech, Inc., ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it ...

Am J Health Syst Pharm. 2006;63(11):1022-1028. Q: How can potential medication errors be minimized when dispensing investigational drugs to better ensure patient safety and improve adherence to ...

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...

The review and approval timeline is approximately 45 days ... repeated local reviews of a study application. For investigational new drug (IND) studies, submission can be done via the JIRB ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 ...

That is how the nitrogen-editing works regarding drugs. By inserting nitrogen at select places, we can make new drugs from existing drugs with new properties that treat other conditions.” Since the ...

Changes in Opioid Use Outcomes After Passage of Medical Marijuana Laws Jan. 13, 2025 — A new study found no changes in opioid outcomes among the general population with the states' passage of ...

The companies said they will jointly advance MDX-2201 to an investigational new drug (IND) application filing seeking approval to start human testing, but didn’t give a timeline for that objective.

Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for ...

Agios Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$1.44 compared to the forecast of -$1.68. The company also ...